HB2033 repeals and replaces Missouri’s existing section 191.1720 with a new law titled the “Missouri Save Adolescents from Experimentation (SAFE) Act.” The bill defines a series of terms related to sex, gender transition, cross-sex hormones, puberty-blocking drugs, and gender transition surgery, and then prohibits health care providers from performing gender transition surgery on anyone under 18. It also prohibits prescribing or administering cross-sex hormones or puberty-blocking drugs to minors for the purpose of gender transition, with a limited grandfathering provision for minors who were already receiving those treatments before August 28, 2023, and before March 1, 2027.
The bill creates significant enforcement mechanisms. A violation is deemed unprofessional conduct and requires revocation of the provider’s license by the appropriate licensing or disciplinary board. It also creates a private cause of action against providers, with a long limitations period, a rebuttable presumption of harm in certain infertility cases, mandatory damages provisions, treble damages, attorney’s fees, and court costs. The bill includes confidentiality protections for plaintiffs, limits on waivers, and exceptions for speech protected by the First Amendment, certain disorders of sex development, treatment of complications caused by transition-related care, and emergency treatment for physical disorders or injuries posing imminent danger.
In practical terms, the bill would substantially restrict gender-affirming medical care for minors in Missouri and expose providers to both professional discipline and civil liability. It would also affect licensing boards, courts, physicians, and other health care providers, while carving out narrow exceptions for intersex conditions and emergency medical situations. The measure is framed as a repeal-and-replace of the existing statute, so it would become the controlling state law on this subject if enacted.
The general sentiment reflected in the voting history suggests the bill had majority support in the House, passing third reading with 102 yeas to 45 nays on one recorded vote and 102 yeas to 40 nays on another. The bill’s title and structure indicate a strongly protective, restrictive approach toward youth gender-transition treatment, which likely aligns with supporters’ view that it safeguards minors. The absence of committee transcript material limits direct insight into debate, but the recorded opposition indicates substantial concern from some lawmakers.
The main points of contention are likely the prohibition on gender-affirming care for minors, the retroactive or transitional treatment of patients already receiving care, and the bill’s aggressive enforcement scheme, especially the mandatory license revocation and expanded civil remedies. Opponents would likely focus on medical decision-making, patient access, and the impact on transgender youth and their families, while supporters would emphasize child protection, medical risk, and the bill’s exceptions for intersex conditions and emergencies.
HB2033 would repeal and replace Missouri’s current statute on gender transition procedures, establishing a new section 191.1720 that bans gender transition surgery for minors and bars cross-sex hormones and puberty-blocking drugs for gender transition purposes in individuals under 18, subject to limited grandfathering for some existing patients. It would also impose mandatory professional discipline, including license revocation, and create a private civil cause of action with enhanced damages and attorney’s fees. The bill would directly affect health care providers, licensing boards, courts, and minors seeking gender-affirming care, while preserving narrow exceptions for disorders of sex development, treatment of complications, and emergency care.
The available voting history indicates the bill had clear majority support in the House, with recorded third-reading votes of 102 yeas to 45 nays and 102 yeas to 40 nays. That suggests the measure was generally favored by a substantial bloc of lawmakers, though not unanimously. The bill’s later status of “Voted Do Pass (S)” indicates it advanced beyond the House and continued through the legislative process, reflecting continued institutional support among its backers.
The central controversy is the bill’s restriction of gender-affirming medical treatment for minors, especially the ban on puberty blockers and cross-sex hormones and the prohibition on surgery. Another major point of contention is the enforcement structure: automatic license revocation, a private right of action, treble damages, and attorney’s fees create strong penalties that critics may view as punitive and likely to deter providers. Supporters are likely to argue the bill protects children from irreversible treatment and medical experimentation, while opponents are likely to argue it interferes with medically appropriate care, targets transgender youth, and creates legal risk for providers and families. The grandfathering provision and exceptions for intersex conditions and emergencies may have been intended to narrow the bill, but they also likely remained part of the debate over how broadly the restrictions should apply.